To determine the effect of clinical and radiologic disease activity on the rate of thinning of the ganglion cell/inner plexiform (GCIP) layer and the retinal nerve fiber layer in patients with multiple sclerosis (MS) using optical coherence tomography (OCT).
The anterior visual pathway is frequently affected in multiple sclerosis (MS), with 94% to 99% of patients with MS demonstrating optic nerve lesions postmortem. 1,2 Transected and/or demyelinated optic nerve axons are thought to undergo retrograde degeneration. 3 Because these axons are derived from the retinal nerve fiber layer (RNFL), the RNFL atrophies. 4 In turn, the ganglion cell neurons from which these axons originate correspondingly degenerate. 5 Optical coherence tomography (OCT), a reproducible, noninvasive imaging technique, enables high-resolution quantification of retinal structures, [6] [7] [8] [9] and demonstrates peripapillary RNFL thinning in MS eyes with and without a history of optic neuritis (ON). [10] [11] [12] [13] [14] Accordingly, OCT has been proposed as an outcome measure for assessing neuroprotection in MS.
The advent of OCT segmentation enables estimation of macular ganglion cell layer integrity by quantifying the composite thickness of the ganglion cell and inner plexiform (GCIP) layer (figure). [15] [16] [17] GCIP thinning also occurs in MS eyes with and without ON history, although GCIP thickness measures may have better reproducibility and superior structure-function correlations with vision than RNFL thickness measures. 16, 18 Although some studies have assessed longitudinal RNFL change in non-ON MS eyes, 19, 20 the GCIP remains to be explored longitudinally. Moreover, the effect of MS disease activity on the rate of retinal neurodegeneration remains largely unexamined, an issue relevant for both the clinical utility of OCT and for the design of future trials utilizing OCT as an outcome. Our hypothesis was that patients with greater nonocular disease activity will have more neuroaxonal damage that will be measurable as more rapid thinning of the RNFL and GCIP layer.
METHODS Patients. Patients with MS or clinically isolated syndromes (CIS) were enrolled from the Johns Hopkins MS Center. Participants underwent clinical evaluations and OCT every 6 months, as well as annual brain MRI scans. Patients with ,6 months of clinical follow-up were excluded from analysis. MS diagnosis was based on 2005 McDonald criteria. 21 Patients with CIS had experienced an initial CNS inflammatory attack with MRI features compatible with MS, but did not fulfill MS diagnostic criteria. Patients with diabetes, glaucoma, refractive errors of 66 diopters, or other ophthalmologic or neurologic disorders (other than MS) were excluded. Because acute swelling temporarily increases the RNFL thickness, patients with acute ON or evidence of optic disc swelling on fundoscopy within 3 months of baseline assessment, or during study follow-up, were excluded. Data from 9 patients were excluded for the following reasons: inadequate signal strength on baseline scan, glaucoma, diabetes, refractive error .6 diopters, revision of MS diagnosis, central serous chorioretinopathy (2 patients), and development of acute ON during the study (2 patients). Healthy controls (HCs) were recruited from among medical center staff. HCs were invited for OCT scans annually. HCs with ,12 months of follow-up were excluded from analysis.
Standard protocol approvals, registrations, and patient consents. Johns Hopkins University and University of Texas
Southwestern Medical Center Institutional Review Board approvals were obtained, and all participants provided written informed consent.
Clinical data. Patients were classified as having CIS, relapsingremitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS). Expanded Disability Status Scale (EDSS) scores were determined by a certified EDSS examiner at study visits. 22 Baseline disease duration and EDSS scores were used to determine subjects' baseline Multiple Sclerosis Severity Scale (MSSS) scores. 23 Optical coherence tomography. Retinal imaging was performed using Cirrus HD-OCT (model 4000) with software version 5.0 (Carl Zeiss Meditec, Dublin, CA), as described in detail elsewhere. 26 Peripapillary data were obtained with the Optic Disc Cube 200 3 200 protocol. Macular data were obtained using the Macular Cube 512 3 128 protocol. OCT scanning was performed by 3 trained technicians who monitored scans to ensure reliable fixation. Scans with signal strength ,7/10 or with artifact were excluded from analysis. Macular Cube scans were further analyzed in a blinded manner using segmentation software, as previously described by our group. 16, 17 The interrater reproducibility of the GCIP measurement was previously found to be very high in both MS patients and HCs (intraclass correlation 0.99 for both groups). 15 Visual function. Standardized visual function testing was performed with retro-illuminated eye charts of constant light source in a darkened room. High-contrast Early Treatment of Diabetic Retinopathy Study charts (at 4 m) and low-contrast Sloan letter charts (2.5% and 1.25% contrast at 2 m) were used. Testing was performed monocularly, with subjects using their habitual distance spectacles or contact lenses as needed for corrected vision. High-contrast visual loss was defined as a decrease of $5 letters during follow-up, and low-contrast (both 2.5% and 1.25%) visual loss was defined as a decrease of $7 letters during follow-up, in accordance with previously published data. 19, 27, 28 Eyes with baseline high-contrast letter-acuity scores of ,5 letters, or baseline 2.5%-or 1.25%-contrast letter-acuity scores of ,7 letters were excluded from visual loss analyses, because these eyes could not fulfill visual loss criteria.
Statistical analyses. Statistical analysis was completed on STATA version 11 (StataCorp, College Station, TX). Analyses included both eyes of participants. Mixed-effects linear regression adjusting for age and sex, accounting for within-subject intereye correlations, was used to assess differences between baseline OCT measures and visual function between patients with MS and HCs. Age and sex were used as covariates because prior studies have found them to be significantly associated with OCT measures. 29 Using time-tovisit from baseline as a continuous variable, annual rates of change in OCT measures were determined using mixed-effects linear regression adjusting for age and sex, accounting for within-subject intereye correlations. Interaction terms with time were used to determine differences in the annual rates of change in OCT measures according to the following characteristics: disease duration mm/year, p , 0.001). Eyes with ON history had on average 9.5 mm lower RNFL thicknesses and 8.4 mm lower GCIP thicknesses than eyes without ON history (p , 0.001 for both). Age or baseline MSSS score was not significantly associated with baseline RNFL or GCIP thicknesses in this cohort. Although RNFL and GCIP thicknesses differed by MS subtype at baseline, these differences were not significant after adjusting for disease duration.
Longitudinal analyses. Clinical and radiologic changes during the study are summarized in table 3, and Several clinical and radiologic characteristics were assessed to determine whether they were associated with more rapid RNFL or GCIP thinning in MS/ CIS (table 4) . This was done using mixed-effects linear regression models adjusting for age and sex. Several markers of disease activity during follow-up were associated with greater rates of GCIP thinning in patients, as compared with those without these features: nonocular relapses (42% faster; 20.55 vs 20.32 mm/year, Clinical and radiologic markers of MS disease activity were not associated with RNFL thinning, unlike GCIP thinning, although prior ON in eyes was associated with a trend toward a greater rate of RNFL thinning (78% faster; 20.41 vs 20.09 mm/year in eyes without prior ON, p 5 0.07). 
DISCUSSION
In this study, we demonstrate that MS-related subclinical optic neuropathy, and the neurodegeneration associated with this process, occurs more significantly in patients exhibiting classic evidence of clinical and/or radiologic disease activity. This suggests that clinical trials enriched with patients with active MS may have better power to detect neuroprotective effects of novel therapeutic agents. Moreover, our findings suggest that the basis for subclinical optic neuropathy/subclinical optic nerve neurodegeneration may at least be partially related to microscopic optic nerve inflammatory disease. GCIP thinning was accelerated in patients exhibiting evidence of disease activity such as non-ON relapses, new T2 lesions, and new gadolinium-enhancing lesions. Patients exhibiting disability progression also were found to have faster rates of GCIP thinning. Furthermore, rates of GCIP thinning were faster in those with disease duration ,5 years, which may reflect a greater availability of retinal ganglion cells for neurodegeneration earlier in the disease course, or a greater tendency for inflammatory disease activity earlier in the disease course. Rates of GCIP thinning were also augmented when these independent factors were present in combination. For example, patients with new T2 lesions, new enhancing lesions, and disease durations ,5 years exhibited 70% faster rates of GCIP thinning. These results provide evidence that longitudinal GCIP changes in MS may be clinically meaningful and associated with more aggressive inflammatory disease. In addition, GCIP thinning was observed in all MS subtypes, suggesting GCIP neurodegeneration occurs throughout the disease course, perhaps related to microscopic inflammation. Although overall rates of GCIP thinning were significantly greater in patients with MS than in HCs, the rate of GCIP thinning observed in patients with MS is relatively modest. However, the mean duration of this study was short and presented results are expressed as annualized rates of thinning, rather than total thickness reduction between study beginning and study end. Although baseline RNFL results in this study are consistent with prior studies, 10-14 the rate of RNFL thinning in this study (20.21 mm/year) was lower than that observed in some other studies, and was not significantly different from HCs. In one study, the rate of RNFL thinning in MS was 22.0 mm/year, 19 and in another it was 22.7 mm/year. 20 In the latter study, a rate of RNFL thinning of 21.4 mm/year was also observed in HCs. Our results, however, are more in line with 2 other studies in which no significant decrease was observed in RNFL thickness during follow-up. 30, 31 Discrepancies in RNFL change across studies may relate to differences in cohort characteristics. Our results raise the possibility that rates of RNFL thinning may be greater in cohorts with larger proportions of patients with prior ON. Also, another source of potential difference is that the rates we report control for several disease characteristics, whereas some other studies have reported unadjusted rates. Differences in the use of disease-modifying medication could also account for different results. Although all studies excluded patients who developed ON during follow-up, an important factor still bearing consideration is the differential effect of optic nerve inflammation on RNFL and GCIP thicknesses. 17 Our finding that rates of GCIP thinning are accelerated in those with nonocular disease activity suggests that retinal changes in MS may be reflective of more global CNS processes, consistent with cross-sectional observations. 32, 33 However, the mechanism by which retinal changes may reflect global CNS processes is unclear. One plausible explanation is that disruption of the blood-brain barrier in one part of the CNS (reflected for example by an enhancing lesion) may represent a susceptibility for the blood-brain barrier to become disrupted elsewhere, such as in the optic nerves (even though it may be subclinical). If this was the case, it could imply that microinflammatory processes may be occurring within the optic nerves of patients with MS. Because optic nerve inflammation is associated with RNFL swelling but not GCIP swelling, 17 these processes could result in the pseudonormalization or swelling of the RNFL, thus underestimating the true rates of RNFL thinning. The absence of GCIP swelling during optic nerve inflammation, as well as the absence of astroglial influence on GCIP thickness measures (the retinal astrocytes are predominantly located in the RNFL), 16, 34 may help explain the superiority of GCIP thickness measures over RNFL thickness measures, cross-sectionally and longitudinally. These factors may contribute toward the better reproducibility and lower variance of GCIP over RNFL thickness measures. 16 It was surprising in this study that expected associations between worsening vision and changes in OCT measures were not observed, because these measures correlate well cross-sectionally. 8, 9 However, changes in visual acuity can have multiple causes in MS (e.g., posterior visual pathway lesions, refractive changes, temporary changes due to Uhthoff phenomenon), potentially weakening the association between changes in OCT and changes in vision in a cohort. Also, much of the change in vision that correlates with change in OCT measures comes from ON episodes. Because data after acute ON episodes were excluded in this study, this likely also weakened the ability to identify an association between change in low-contrast vision and change in OCT. Although patients with other known ocular diseases were excluded, the patients in this cohort were not systematically examined by an ophthalmologist, which limits our ability to correlate the OCT findings with aspects of visual function other than high-and low-contrast vision.
Given the potentially slow rate of change in OCT measures in non-ON MS eyes and nonactive MS, it is possible that a long timeframe may be needed to identify a neuroprotective therapeutic effect in a clinical trial using OCT as an outcome measure (such as in progressive MS). Nonetheless, if used as a secondary outcome, a finding of slower OCT change in treated relative to untreated patients may provide compelling evidence for neuroprotection. OCT has already shown promise as an outcome measure in acute ON, whereby a 10% to 20% change in RNFL thickness occurs within months. 14 As discussed above, GCIP thickness may be a more sensitive measure to detect clinical change in MS than RNFL thickness. Because patients exhibiting active MS in this study, particularly early on in their disease course, had greater rates of GCIP thinning, a clinical trial using OCT as an outcome measure could potentially be enriched by the recruitment of patients with early, active MS. Our results suggest that researchers planning future trials incorporating OCT should consider the inclusion of macular-GCIP thickness measures (which will be commercially available soon), in addition to conventional peripapillary RNFL thickness measures.
